Product Code: GVR-4-68040-003-4
Diagnostic Enzymes Market Growth & Trends:
The global diagnostic enzymes market size is expected to reach USD 6.27 billion by 2030, registering a CAGR of 5.18 % from 2024 to 2030, according to a new report by Grand View Research, Inc. Growth of the diagnostic enzymes market is attributed to rising demand for the enzymes in diagnostics with wide applications in pathology. Moreover, advancements in diagnostic techniques for viral infection are anticipated to propel the market growth.
Diagnostic enzymes are widely adopted owing to the higher sensitivity and accuracy offered by enzyme activity. The enzyme activities can be earlier than clinical signs and other diagnostic indicators. Biosensors are becoming a popular potential tool for medical diagnostics, pathogen detection, and monitoring. Biosensors have gained popularity owing to the accuracy, sensitivity, selectivity, and rapid detection strategies that can be used routinely. Diagnosis of serum levels of the enzymes has been used as an indicator of the cellular damage that results in the release of the intercellular components into the bloodstream.
Viral infections of the respiratory tract are among the most common disorders in humans, and the ones caused due to the outbreak of emerging viruses, such as COVID-19, have posed a threat to public health. Therefore, detection of the viral pathogens is vital to stop the occurrence of such epidemics and prevent the unnecessary use of antibiotics. Therefore, novel diagnostic strategies have been adopted by the key players. LightMix (Roche Molecular Diagnostics, Switzerland), AccuPower (Bioneer, Korea), PowerChek (Kogene Biotech, Korea), Anyplex (Seegene, Korea), UltraFast kits (Nanobiosys, Korea), and DiaPlexQ (SolGent, Korea) are some of the commercially available RT-PCR kits for MERS-CoV RNA detection with sensitivities as high as 99.03%.
An increase in the number of diagnostic enzyme tests has led to a boost in recommendations and guidelines with a number of publications on their performance. Moreover, reimbursement pathways lack clear guidelines and systematic Health Technology Assessment (HTA). Various factors influencing payer decisions for diagnostic enzyme tests include FDA clearance, physician support & clinical guidelines, competitor coverage policies, cost/benefit analyses, results of HTAs, and employer or advocacy group demands.
Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in March 2022, Meridian Bioscience, Inc. launched two master mixes, which can be used in non-invasive liquid biopsy. The launch of such breakthrough technologies enables better analysis of the performance levels as compared to traditional qPCR from the purified nucleic acid.
Diagnostic Enzymes Market Report Highlights:
- In 2023, the glucose oxidase/glucose dehydrogenase enzyme segment held a dominant share in the market owing to the presence of an abundance of enzymes in living organisms
- The oncology segment is projected to grow at the fastest rate during the forecast period owing to the increasing prevalence of cancer among the population
- The clinical segment is the highest revenue-generating segment in 2023 owing to the increased focus on R&D
- The diagnostic enzyme market is witnessing change owing to the presence of key market players focusing on product launches and geographic expansion to maintain their position in the market
- Asia Pacific is expected to witness the fastest growth during the forecast period owing to the improved manufacturing facilities and the presence of the target population
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. Product
- 1.2.4. End Use
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type and Application outlook
- 2.2.2. Product outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Diagnostic Enzymes Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rise in the demand for enzymes in pathology
- 3.2.1.2. Wide applications of enzymes in pathology
- 3.2.1.3. Advancements in diagnostic testing of viral infection
- 3.2.1.4. Increase in the demand for Point-of-Care testing
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of enzyme-based diagnostic tests
- 3.2.2.2. Regulatory & reimbursement hurdles for enzyme diagnostics
- 3.3. Diagnostic Enzymes Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
Chapter 4. Diagnostic Enzymes Market: Type Estimates & Trend Analysis
- 4.1. Global Diagnostic Enzymes Market: Type Dashboard
- 4.2. Global Diagnostic Enzymes Market: Type Movement Analysis
- 4.3. Global Diagnostic Enzymes Market by Treatment, Revenue
- 4.4. Taq Polymerase
- 4.4.1. Taq Polymerase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. MMLV RT
- 4.5.1. MMLV RT market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. HIV RT
- 4.6.1. HIV RT market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Hot Start Taq Pol
- 4.7.1. Hot Start Taq Pol market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. UNG
- 4.8.1. UNG market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Rnase Inhibitors
- 4.9.1. Rnase Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
- 4.10. Bst Polymerase (LAMP ENZYME)
- 4.10.1. Bst Polymerase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.11. PCR Master Mix
- 4.11.1. PCR Master Mix market estimates and forecasts 2018 to 2030 (USD Million)
- 4.12. Lyophilized Polymerase
- 4.12.1. Lyophilized Polymerase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.13. T7 Rna Polymerase
- 4.13.1. T7 Rna Polymerase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.14. Cas9 Enzyme
- 4.14.1. Cas9 Enzyme market estimates and forecasts 2018 to 2030 (USD Million)
- 4.15. Acid Phosphatase
- 4.15.1. Acid Phosphatase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.16. Alanine Aminotransferase
- 4.16.1. Alanine Aminotransferase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.17. Alkaline Phosphatase
- 4.17.1. Alkaline Phosphatase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.18. Amylase
- 4.18.1. Amylase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.19. Angiotensin Converting Enzyme
- 4.19.1. Angiotensin Converting Enzyme market estimates and forecasts 2018 to 2030 (USD Million)
- 4.20. Aspartate Aminotransferase
- 4.20.1. Aspartate Aminotransferase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.21. Cholinesterase
- 4.21.1. Cholinesterase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.22. Creatinine Kinase
- 4.22.1. Creatinine Kinase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.23. Gamma Glutamyl Transferase
- 4.23.1. Gamma Glutamyl Transferase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.24. Lactate Dehydrogenase
- 4.24.1. Lactate Dehydrogenase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.25. Renin
- 4.25.1. Renin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.26. Glucose Oxidase/Glucose Dehydrogenase
- 4.26.1. Glucose Oxidase/Glucose Dehydrogenase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.27. Urease
- 4.29.1. Urease market estimates and forecasts 2018 to 2030 (USD Million)
- 4.28. Lactate Oxidase
- 4.31.1. Lactate Oxidase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.29. Horseradish Peroxide
- 4.33.1. Horseradish Peroxide market estimates and forecasts 2018 to 2030 (USD Million)
- 4.30. Glutamate Oxidase
- 4.35.1. Glutamate Oxidase market estimates and forecasts 2018 to 2030 (USD Million)
- 4.31. Others
- 4.31.1. Others Oxidase market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Diagnostic Enzymes Market: Application Estimates & Trend Analysis
- 5.1. Global Diagnostic Enzymes Market: Application Dashboard
- 5.2. Global Diagnostic Enzymes Market: Application Movement Analysis
- 5.3. Global Diagnostic Enzymes Market Estimates and Forecasts, By Application, Revenue (USD Million)
- 5.4. Diabetes
- 5.4.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Oncology
- 5.5.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Cardiology
- 5.6.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Infectious Disease
- 5.7.1. Infectious Disease market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Nephrology
- 5.8.1. Nephrology market estimates and forecasts 2018 to 2030 (USD Million)
- 5.9. Autoimmune Diseases
- 5.9.1. Autoimmune Diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 5.10. Others
- 5.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Diagnostic Enzymes Market: Product Estimates & Trend Analysis
- 6.1. Global Diagnostic Enzymes Market: Product Dashboard
- 6.2. Global Diagnostic Enzymes Market: Product Movement Analysis
- 6.3. Global Diagnostic Enzymes Market Estimates and Forecasts, by Product, Revenue (USD Million)
- 6.4. Molecular Enzymes
- 6.4.1. Molecular Enzymes market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Clinical Enzymes
- 6.5.1. Clinical Enzymes market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Diagnostic Enzymes Market: End Use Estimates & Trend Analysis
- 7.1. Global Diagnostic Enzymes Market: End Use Dashboard
- 7.2. Global Diagnostic Enzymes Market: End Use Movement Analysis
- 7.3. Global Diagnostic Enzymes Market Estimates and Forecasts by End Use, Revenue (USD Million)
- 7.4. Hospital
- 7.4.1. Hospital market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Clinical Laboratories
- 7.5.1. Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Others End -users
- 7.6.1. Others End -users market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Diagnostic Enzymes Market: Regional Estimates & Trend Analysis by Type, Application, Product and End Use
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.3. North America
- 8.3.1. U.S.
- 8.3.1.1. Key country dynamics
- 8.3.1.2. Regulatory framework/ reimbursement structure
- 8.3.1.3. Competitive scenario
- 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.3.2. Canada
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Regulatory framework/ reimbursement structure
- 8.3.2.3. Competitive scenario
- 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.3.3. Mexico
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Regulatory framework/ reimbursement structure
- 8.3.3.3. Competitive scenario
- 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Regulatory framework/ reimbursement structure
- 8.4.1.3. Competitive scenario
- 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Regulatory framework/ reimbursement structure
- 8.4.2.3. Competitive scenario
- 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Regulatory framework/ reimbursement structure
- 8.4.3.3. Competitive scenario
- 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Regulatory framework/ reimbursement structure
- 8.4.4.3. Competitive scenario
- 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Regulatory framework/ reimbursement structure
- 8.4.5.3. Competitive scenario
- 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.6. Norway
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Regulatory framework/ reimbursement structure
- 8.4.6.3. Competitive scenario
- 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Regulatory framework/ reimbursement structure
- 8.4.7.3. Competitive scenario
- 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Regulatory framework/ reimbursement structure
- 8.4.8.3. Competitive scenario
- 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. China
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. India
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework/ reimbursement structure
- 8.5.3.3. Competitive scenario
- 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. Australia
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework/ reimbursement structure
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.5. South Korea
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Regulatory framework/ reimbursement structure
- 8.5.5.3. Competitive scenario
- 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Regulatory framework/ reimbursement structure
- 8.5.6.3. Competitive scenario
- 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Vendor Landscape
- 9.2.1. List of key distributors and channel partners
- 9.2.2. Key customers
- 9.2.3. Key company market share analysis, 2023
- 9.2.4. Takara Bio, Inc.
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Product benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. Promega Corporation
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. Enzo Biochem Inc.
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Merck KGaA
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. Thermo Fisher Scientific, Inc.
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Product benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. Creative Enzymes
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Product benchmarking
- 9.2.9.4. Strategic initiatives
- 9.2.10. F. Hoffmann-La Roche Ltd.
- 9.2.10.1. Company overview
- 9.2.10.2. Financial performance
- 9.2.10.3. Product benchmarking
- 9.2.10.4. Strategic initiatives
- 9.2.11. Solis BioDyne.
- 9.2.11.1. Company overview
- 9.2.11.2. Financial performance
- 9.2.11.3. Product benchmarking
- 9.2.11.4. Strategic initiatives
- 9.2.12. Ambliqon A/S.
- 9.2.12.1. Company overview
- 9.2.12.2. Financial performance
- 9.2.12.3. Product benchmarking
- 9.2.12.4. Strategic initiatives
- 9.2.13. Yashraj Biotechnology Ltd.
- 9.2.13.1. Company overview
- 9.2.13.2. Financial performance
- 9.2.13.3. Product benchmarking
- 9.2.13.4. Strategic initiatives